| Ytd | -24.06% | |
| 1y | -34.15% |
| Open | 38.11 | Prev Close | 38.18 | Low | 38.06 | High | 38.68 | Mkt Cap | 170.57B |
| Vol | 9.65M | Avg Vol | 12.64M | EPS | 4.09 | P/E | 9.45 | Forward P/E | 11.67 |
| Beta | 0.38 | Short Ratio | 2.51 | Inst. Own | 9.89% | Dividend | 1.80 | Div Yield | 4.71 |
| Ex Div Date | 08-17 | Earning | 11-04 | 50-d Avg | 43.69 | 200-d Avg | 45.45 | 1yr Est | 46.09 |
NVO News
Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk comman
UBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaro
PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its au
Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to
Novo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% chan
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock grow
Novo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weig
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it
Eli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth. Novo N
Eastern Bank decreased its stake in Novo Nordisk A/S (NYSE: NVO) by 32.8% during the undefined quart
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical effic
FDA extends review for Novo Nordisk's denecimig over manufacturing remediation. Financial outloo
Novo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited. Pfizer hasn't en
Anthropic launches a $100 million academy to train 10,000 AI engineers by 2027 as demand for AI tale
https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denec
Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle pr
Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post ho
Novo Nordisk today presented post hoc analysis of datafrom a STEP UP trial sub-population with 55 pa
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Novo Nordisk presents data showing CagriSema reduces cravings and weight, while real-world patients
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 b
Eli Lilly says Zepbound and Foundayo provide superior weight loss and blood sugar control over Novo
Novo’s Ozempic (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events
HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Tot
Anthropic’s Claude enzyme discovery claim faces scrutiny after a biologist questioned whether prior
New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care:
Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is strug
Novo Nordisk eyes M&A to counter patent cliff risks, and partners with Nanexa for long-acting in
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosi
Anthropic and OpenEvidence are giving doctors in nearly 100 poorer nations free access to medical gu
https://www.ft.com/content/00d53ca3-725f-4fa8-b452-cef562a13514?syn-25a6b1a6=1
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts c
Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
U.S. stocks climbed Monday, led by Nasdaq (+1.77%) and Intel (+10%); communication shares rallied, w
Novo Nordisk targets 2026-2030 growth, and unveils Phase 3 CagriSema results beating Eli Lilly's
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other
Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of o
A US congressman sold some Magnificent Seven stocks and replaced them with a couple consumer staples
PrSandoz® Semaglutide, a generic version of PrOzempic®, approved for the treatment of adult patients
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
Novo Nordisk wins CHMP recommendation for hemophilia drug FREHEMGO and enters a $1.4 billion cardiom
https://www.globenewswire.com/news-release/2026/09/17/3364155/0/en/novo-chmp-recommends-eu-approval-
Artelo Biosciences shares new nonclinical data showing its oral cannabinoid drug ART27.13 matches se
Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement
Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates
Novo Nordisk rebrands as 'Novo' as it seeks to regain obesity drug market share and unveils
Analysts downgraded Novo Nordisk, Chewy, NuScale Power and Atmos Energy, cutting price targets for t